Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer's disease.
about
The coexistence of an equal amount of Alzheimer's amyloid-β 40 and 42 forms structurally stable and toxic oligomers through a distinct pathwayA comparative analysis of the aggregation behavior of amyloid-β peptide variantsThe potential of pathological protein fragmentation in blood-based biomarker development for dementia - with emphasis on Alzheimer's diseaseA window into the heterogeneity of human cerebrospinal fluid Aβ peptidesBrain pyroglutamate amyloid-β is produced by cathepsin B and is reduced by the cysteine protease inhibitor E64d, representing a potential Alzheimer's disease therapeuticBACE1 inhibition induces a specific cerebrospinal fluid β-amyloid pattern that identifies drug effects in the central nervous systemPurification and Characterization of Recombinant N-Terminally Pyroglutamate-Modified Amyloid-β Variants and Structural Analysis by Solution NMR SpectroscopyStructural Analysis and Aggregation Propensity of Pyroglutamate Aβ(3-40) in Aqueous TrifluoroethanolAβ40 oligomers identified as a potential biomarker for the diagnosis of Alzheimer's diseaseCortical pyroglutamate amyloid-β levels and cognitive decline in Alzheimer's disease.Pyroglutamate amyloid β (Aβ) aggravates behavioral deficits in transgenic amyloid mouse model for Alzheimer disease.Highly potent soluble amyloid-β seeds in human Alzheimer brain but not cerebrospinal fluidCerebrospinal fluid-induced retardation of amyloid β aggregation correlates with Alzheimer's disease and the APOE ε4 allele.Focusing the amyloid cascade hypothesis on N-truncated Abeta peptides as drug targets against Alzheimer's diseaseThe Case for Abandoning Therapeutic Chelation of Copper Ions in Alzheimer's DiseaseMammalian Metallothionein-3: New Functional and Structural InsightsDistinct synthetic Aβ prion strains producing different amyloid deposits in bigenic mice.Immunoprecipitation of amyloid fibrils by the use of an antibody that recognizes a generic epitope common to amyloid fibrils.Pyroglutamate-amyloid-β and glutaminyl cyclase are colocalized with amyloid-β in secretory vesicles and undergo activity-dependent, regulated secretion.The amyloid-β isoform pattern in cerebrospinal fluid in familial PSEN1 M139T- and L286P-associated Alzheimer's diseaseβ-Secretase-1 elevation in aged monkey and Alzheimer's disease human cerebral cortex occurs around the vasculature in partnership with multisystem axon terminal pathogenesis and β-amyloid accumulation.Oligomers, fact or artefact? SDS-PAGE induces dimerization of β-amyloid in human brain samples.Amyloid beta dimers/trimers potently induce cofilin-actin rods that are inhibited by maintaining cofilin-phosphorylationOverexpression of glutaminyl cyclase, the enzyme responsible for pyroglutamate A{beta} formation, induces behavioral deficits, and glutaminyl cyclase knock-out rescues the behavioral phenotype in 5XFAD mice.Glutaminyl cyclase contributes to the formation of focal and diffuse pyroglutamate (pGlu)-Aβ deposits in hippocampus via distinct cellular mechanismsSite-specific characterization of threonine, serine, and tyrosine glycosylations of amyloid precursor protein/amyloid beta-peptides in human cerebrospinal fluidIsoglutaminyl cyclase contributes to CCL2-driven neuroinflammation in Alzheimer's disease.Pyroglutamyl-N-terminal prion protein fragments in sheep brain following the development of transmissible spongiform encephalopathies.Pyroglutamate amyloid-β (Aβ): a hatchet man in Alzheimer diseaseAmyloid-β-induced amyloid-β secretion: a possible feed-forward mechanism in Alzheimer's Disease.Probing amyloid-β pathology in transgenic Alzheimer's disease (tgArcSwe) mice using MALDI imaging mass spectrometry.First effects of rising amyloid-β in transgenic mouse brain: synaptic transmission and gene expression.Alzheimer therapy with an antibody against N-terminal Abeta 4-X and pyroglutamate Abeta 3-X.Utility of an improved model of amyloid-beta (Aβ₁₋₄₂) toxicity in Caenorhabditis elegans for drug screening for Alzheimer's diseaseCerebral white matter lesions - associations with Aβ isoforms and amyloid PETDeposition of C-terminally truncated Aβ species Aβ37 and Aβ39 in Alzheimer's disease and transgenic mouse models.Amyloid-β Peptide Aβ3pE-42 Induces Lipid Peroxidation, Membrane Permeabilization, and Calcium Influx in Neurons.Distinct patterns of APP processing in the CNS in autosomal-dominant and sporadic Alzheimer diseaseSequence proximity between Cu(II) and Cu(I) binding sites of human copper transporter 1 model peptides defines reactivity with ascorbate and O2.N-truncated amyloid β (Aβ) 4-42 forms stable aggregates and induces acute and long-lasting behavioral deficits.
P2860
Q24294387-820677E7-5665-47BB-BB6D-B2E7E372F048Q24301848-70C1E8F2-F61D-47A6-A985-8D5162301E5BQ26853347-C634C644-6E7D-4580-90FD-93BCD2329C8CQ27010785-9CD85EAF-57C9-4D79-8969-41737EE884A1Q28235248-76682600-FAAC-47EE-93FF-73A2EB869F09Q28480522-81F10CED-0C2B-42F0-B49D-9042E0C80C41Q28550062-ECE8733E-2A06-49F8-8113-48F758A79C63Q28551142-890970DF-82B3-4C53-BC0C-D5AA87E10EE7Q28743838-6BE0168A-1E21-4ED0-8A7E-5424F7A6709EQ30361851-11BF1B99-CE5E-430D-8FE1-428BCB853F7EQ30512697-D73B8595-8A8F-4CF0-9599-FD756271D9B5Q30842997-F16FC508-1FF0-4D71-BC9D-2738D75B63D3Q33363912-6A559305-C833-4C52-8BC0-0E6E48868452Q33624303-E505C597-A141-434A-BEAF-96E5AEF4AE92Q33755982-3D0B8BC2-709E-4F6C-AD5B-69674B5DB369Q33838378-5842DC23-90F6-4603-890E-1533943F2D4AQ33925689-5CD104E8-687D-4D6A-87A7-98A4C9C58056Q34075450-55AF043B-12A1-4D58-ACE2-8F1F89793EEDQ34076284-0D85FDAA-7DF1-43CD-8DA0-1D61EE466A84Q34151493-FA3464CF-AECF-4BFD-B8BE-7C904757F95DQ34268487-76A59F89-3260-41DE-994E-006705761679Q34564863-AB6FED7A-CC58-4EB3-A71C-296F0AD30455Q34567280-3CD14909-54A4-44CD-8079-9F169AD20C2CQ34575806-9DBBEA37-71FE-407C-8988-03476B0335C3Q34995785-98A28C29-6B1D-43FB-B021-A396011A6D03Q35123119-9309DCA5-3237-428F-8648-475DE5789C04Q35197124-2495ED0A-743B-47D2-B472-709E0BCF4C72Q35600113-03D0E2D7-FCDA-4733-AA33-9DC0C045A46BQ35604177-E33AD6B9-A602-46B8-A284-8C5F08955D76Q35659998-B0108BF6-7757-40F0-8903-88E028AF8344Q35999472-417FCDF3-17E5-4E91-B255-4D2A22125323Q36066679-2991667B-A36F-4FDA-A482-C250AF5491F6Q36340365-0B7E664C-1B1D-4F78-B5AB-AA151550379DQ36460071-CE235E46-8AEB-468D-BAF1-F0EA69D82B95Q36559869-D99C7622-07B4-4BCC-AEA9-44D5BB193DE1Q36668200-3F842182-D2C0-43BA-A6CC-2BAA9051E070Q36744769-B230DA5A-52AB-4832-9B0A-F8AE7AF8059FQ36756941-DB28B709-AB8E-4A60-A8D8-95DD1F1789A7Q36952094-7D1EF2E7-7327-43E5-B1E4-6514ED9DB18AQ37043304-EC53C3B3-6707-48C2-B8CF-77B1D5D24581
P2860
Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer's disease.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Mass spectrometric characteriz ...... sporadic Alzheimer's disease.
@ast
Mass spectrometric characteriz ...... sporadic Alzheimer's disease.
@en
type
label
Mass spectrometric characteriz ...... sporadic Alzheimer's disease.
@ast
Mass spectrometric characteriz ...... sporadic Alzheimer's disease.
@en
prefLabel
Mass spectrometric characteriz ...... sporadic Alzheimer's disease.
@ast
Mass spectrometric characteriz ...... sporadic Alzheimer's disease.
@en
P2093
P2860
P50
P1476
Mass spectrometric characteriz ...... sporadic Alzheimer's disease.
@en
P2093
Inga Volkmann
Mikael K Gustavsson
Nenad Bogdanovic
P2860
P2888
P304
P356
10.1007/S00401-010-0690-1
P577
2010-04-24T00:00:00Z